# Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)

> **NCT03434353** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 123 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Inarigivir Soproxil
- **DRUG:** TAF

## Key facts

- **NCT ID:** NCT03434353
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-28
- **Primary completion:** 2020-01-20
- **Final completion:** 2021-01-26
- **Target enrollment:** 123 (ACTUAL)
- **Why stopped:** Study was terminated due to sponsor's decision to not pursue further development of inarigivir soproxil in chronic hepatitis B.
- **Last updated:** 2022-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03434353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03434353, "Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03434353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*